Trinity Chiesi
Site Map
Home
Introduction
Research & Development
Opportunities
Product Information
Contact Details
Quest
Fast Facts
The Chiesi Group employs 2,700 people globally
Last year, we invested €69.524 million in R&D
Our unique Modulite® technology platform is commercialised across Europe, producing CFC-free inhalers
We excel in providing modified-release drugs and respiratory medicines
Trinity-Chiesi's number one product in the UK is MonomaxTM, the volume market leader in its class
Legal Disclaimer : Privacy Statement

Welcome to Trinity-Chiesi Pharmaceuticals

By browsing these pages you can find out who we are and what we do - and maybe catch some of our passion for innovation.

Putting the patient at the heart of our business

Our parent company, Chiesi, is a leading European pharmaceutical company, based in Parma, Italy, with affiliates throughout Europe, and in the US, Brazil and Pakistan.

Trinity-Chiesi is dedicated to the research, development and commercialisation of ethical, therapeutic products.


A dynamic partnership for 21st century pharmaceuticals
Trinity's 10-year track record in the UK market + Chiesi's long-established research and innovative capability = a credible and dynamic partnership for the 21st century.

 

 

"Trinity and Chiesi each has a very different heritage but together they are the perfect fit"

- Managing Director, Trinity-Chiesi Pharmaceuticals

 

Therapy areas

Trinity-Chiesi currently delivers a range of medicines in the following areas:

Making things happen
We have a lot planned for the next 5 years. Trinity-Chiesi values its people and their ideas. View current  opportunities 

if you are interested in contributing to this exciting phase of our development.

 

What's in the pipeline?

The Trinity-Chiesi R&D pipeline is not a hit-and-miss affair; our Modulite® technology  guarantees product delivery. Quite simply, our pipeline offers deliverable products, based on provable concepts.